ArticleEJNMMI research2017
Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis.
Article in EJNMMI research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Effects of dose heterogeneity on response and toxicity afterEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Tumor Absorbed Dose Predicts Survival and Local Tumor Control in Colorectal Liver Metastases Treated with 90Y Radioembolization.Cardiovascular and interventional radiology · 2026Article
- Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy.Biomedicines · 2025Review
- Theranostic Radioembolization: Radiation Dosimetry-Guided Treatment Planning and Delivery.World journal of nuclear medicine · 2025Review
- Quantitative evaluation ofMedical physics · 2024Article
- Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study.The British journal of radiology · 2024Article
- Stereotactic body radiation therapy (SBRT) following Yttrium-90 (Physics in medicine and biology · 2023Article
- Trans-arterial Radioembolization Dosimetry in 2022.Cardiovascular and interventional radiology · 2022Review
- Towards personalised dosimetry in patients with liver malignancy treated withEJNMMI physics · 2022Article
- Radioembolization Dosimetry with Total-BodyJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model.EJNMMI physics · 2022Article
- Article
- Comparison ofPhysica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2021Article
- Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects.Molecules (Basel, Switzerland) · 2021Review
- Review
- International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.European journal of nuclear medicine and molecular imaging · 2021Article
- Combined quality and dose-volume histograms for assessing the predictive value ofEJNMMI physics · 2020Article
- Personalized Dosimetry for Liver Cancer Y-90 Radioembolization Using Computational Fluid Dynamics and Monte Carlo Simulation.Annals of biomedical engineering · 2020Article
- Comparative dosimetry betweenEuropean journal of nuclear medicine and molecular imaging · 2020Article
- SimultaneousEJNMMI physics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to investigate the relationship between absorbed dose and response of colorectal cancer liver metastases treated with [
methodsFDG PET/CT was used to measure response of individual lesions to a measured absorbed dose, derived from post-treatment
resultsSixty-three lesions were analysed from 22 patients. Poor agreement was seen between predicted and measured dose values. TLG was a superior measure of response, and all dose metrics were significant prognostic factors, with a D
conclusionsLesions receiving an average dose greater than 50 Gy are likely to have a significant response. For lesions receiving less than 50 Gy, dose heterogeneity is a significant prognostic factor. Lesions receiving an average dose less than 20 Gy are unlikely to respond. A reduction in TLG may be associated with improved overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.